Subcutaneous administration of anti-CD38 antibodies

A subcutaneously administered anti-CD38 antibody with optimized CDR sequences addresses the impracticality of current intravenous treatments by reducing side effects and volume requirements, providing a safer and more effective treatment for CD38-related diseases.

JP2026143565APending Publication Date: 2026-09-08TAKEDA PHARMA CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
JP2026092818
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-03-28
Filing Date
2026-06-02
Publication Date
2026-09-08

AI Technical Summary

Technical Problem

Current anti-CD38 antibodies require high doses and volumes for intravenous administration due to binding to red blood cells, leading to side effects such as hemolytic anemia and infusion-related reactions, making subcutaneous administration impractical.

Method used

Development of a subcutaneously administered anti-CD38 antibody with specific CDR sequences (SEQ ID NOs: 3, 4, 5 for VH; SEQ ID NOs: 6, 7, 8 for VL) that minimizes binding to red blood cells, allowing for safer and more effective treatment of CD38-related diseases.

Benefits of technology

The subcutaneous administration reduces severe adverse events to less than 60% of traditional intravenous treatments, achieving therapeutic efficacy with reduced volume and frequency, minimizing side effects like anemia and thrombocytopenia.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This provides effective treatment methods for cancer, including autoimmune diseases and blood disorders. [Solution] A method for treating a disease in a subject, the method comprising subcutaneously administering a sufficient amount of isolated human anti-CD38 antibody to the subject, wherein the anti-CD38 antibody comprises a variable heavy (VH) chain region having a specific amino acid sequence and a variable light (VL) chain region having another specific amino acid sequence and comprising CDR1, CDR2, and CDR3, the disease is one for which binding to CD38 is indicated, and the antibody is administered in a dosage of 45 to 1,800 milligrams.
Need to check novelty before this filing date? Find Prior Art